APOBEC

Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure

Retrieved on: 
화요일, 9월 26, 2023
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, TRAC, Drug development, Gene editing, PDCD1, CD58, Cancer, Messenger, RNA, Genomics, AstraZeneca, Cell, Cas9, Laboratory, APOBEC, Diagnosis, NYSE, DSM-IV codes, Pin, Vaccine, Pharmaceutical industry, CRISPR

Revvity , Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.

Key Points: 
  • Revvity , Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.
  • The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.
  • The introduction of Pin-point base editing reagents signifies a momentous stride toward democratizing access to base editing.
  • However, with the newly launched reagents, scientists now have the ability to fully evaluate the Pin-point base editing platform in-house.

MGFB announces agreement with Mayo Clinic for development of novel therapeutic cancer vaccines

Retrieved on: 
화요일, 11월 8, 2022
Hope, Acquisition, University of Leeds, Mayo Clinic, Patient, Third party, ASEL, APOBEC, FWB, Hepatocellular carcinoma, Consultant, University, Education, Glioma, Ownership, Antigen, Health, Neoplasm, Mouse, Research, Therapy, Technology, CEO, Pharmaceutical industry, Vaccine

Founding equity ownership in MGFB includes FWB, University of Leeds and Mayo Clinic.

Key Points: 
  • Founding equity ownership in MGFB includes FWB, University of Leeds and Mayo Clinic.
  • The platform is designed to address mutational burden, immune escape, and tumor resistance, commonly seen in many solid tumor patients.
  • MGFB intends to advance multiple programs into the clinic to address indications where current therapeutic options are limited.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.